PE20061058A1 - Composicion farmaceutica que comprende ixabepilona y proceso de preparacion - Google Patents
Composicion farmaceutica que comprende ixabepilona y proceso de preparacionInfo
- Publication number
- PE20061058A1 PE20061058A1 PE2005001348A PE2005001348A PE20061058A1 PE 20061058 A1 PE20061058 A1 PE 20061058A1 PE 2005001348 A PE2005001348 A PE 2005001348A PE 2005001348 A PE2005001348 A PE 2005001348A PE 20061058 A1 PE20061058 A1 PE 20061058A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- preparation process
- pharmaceutical composition
- particle
- enteric coating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA PARTICULA RECUBIERTA QUE ESTA COMPUESTA POR UNA PARTICULA BASE INERTE TALES COMO ALMIDON, CELULOSA MICROCRISTALINA EN UNA CANTIDAD COMPRENDIDA ENTRE 10 A 80% p/p EN PESO DE LA PARTICULA BASE Y UN PRINCIPIO ACTIVO TAL COMO IXABEPILONA EN UNA CANTIDAD COMPRENDIDA ENTRE 0.1% A 50% p/p EN PESO DEL PRINCIPIO ACTIVO CON UN AGLUTINANTE A BASE DE ALMIDON, GELATINA, ENTRE OTROS Y B) UN RECUBRIMIENTO ENTERICO TALES COMO FTALATO DE METILCELULOSA DE HIDROXIPROPILO, FTALATO DE ACETATO DE POLIVINILO, FTALATO DE ACETATO DE CELULOSA, ENTRE OTROS; EN UNA CANTIDAD COMPRENDIDA ENTRE 5 A 55% p/p EN PESO DEL RECUBRIMIENTO ENTERICO. TAMBIEN SE REFIERE A UNA CAPA DE RECUBRIMIENTO INTERPUESTA ENTRE LA CAPA DE PRINCIPIO ACTIVO Y EL RECUBRIMIENTO ENTERICO EN UNA CANTIDAD COMPRENDIDA ENTRE 0.1% A 10% p/p EN PESO DE LA COMPOSICION Y A UN PROCESO DE PREPARACION. DICHA COMPOSICION SE PRESENTA EN FORMA DE PERLAS RECUBIERTAS CONTENIDAS EN CAPSULAS SIENDO UTIL EN EL TRATAMIENTO DEL CANCER U OTRAS ENFERMEDADES PROLIFERATIVAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62897004P | 2004-11-18 | 2004-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061058A1 true PE20061058A1 (es) | 2006-10-13 |
Family
ID=35976527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001348A PE20061058A1 (es) | 2004-11-18 | 2005-11-17 | Composicion farmaceutica que comprende ixabepilona y proceso de preparacion |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060153917A1 (es) |
| EP (2) | EP1817013B1 (es) |
| JP (1) | JP2008520696A (es) |
| KR (1) | KR20070084325A (es) |
| CN (1) | CN101083978A (es) |
| AR (1) | AR052142A1 (es) |
| AT (1) | ATE397442T1 (es) |
| AU (1) | AU2005306464A1 (es) |
| BR (1) | BRPI0518286A2 (es) |
| CA (1) | CA2588400A1 (es) |
| DE (1) | DE602005007376D1 (es) |
| DK (1) | DK1817013T3 (es) |
| ES (1) | ES2306278T3 (es) |
| HK (1) | HK1106713A1 (es) |
| HR (1) | HRP20080349T3 (es) |
| IL (1) | IL183116A0 (es) |
| MX (1) | MX2007005763A (es) |
| NO (1) | NO20072388L (es) |
| PE (1) | PE20061058A1 (es) |
| PL (1) | PL1817013T3 (es) |
| PT (1) | PT1817013E (es) |
| RU (1) | RU2349319C1 (es) |
| SI (1) | SI1817013T1 (es) |
| TW (1) | TW200631609A (es) |
| WO (1) | WO2006055740A1 (es) |
| ZA (1) | ZA200703955B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091725A (zh) | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
| US20110217426A1 (en) * | 2010-03-04 | 2011-09-08 | Perry Stephen C | Enteric coating composition |
| HUE027831T2 (en) | 2010-03-12 | 2016-11-28 | Genzyme Corp | Combination therapy for breast cancer |
| WO2012047802A2 (en) * | 2010-10-01 | 2012-04-12 | The Johns Hopkins University | Systems and methods for high-throughput microfluidic bead production |
| PT2672981T (pt) | 2011-02-11 | 2018-06-21 | Zx Pharma Llc | Dispersão de partículas de polímero num meio não aquoso |
| US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
| US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
| RS58325B1 (sr) | 2013-04-23 | 2019-03-29 | Zx Pharma Llc | Enterosolventno obloženi višečestični preparat sa proteinskom sub-oblogom |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713246A (en) * | 1984-03-19 | 1987-12-15 | Bristol-Myers Company | Etoposide oral dosage form |
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| ES2206607T3 (es) * | 1995-11-17 | 2004-05-16 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Derivados de epotilones, preparacion y utilizacion. |
| JP4090529B2 (ja) * | 1996-01-24 | 2008-05-28 | フロイント産業株式会社 | 乳糖の球形粒及びその製造方法 |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| JP4205168B2 (ja) * | 1996-10-02 | 2009-01-07 | ノバルティス アクチエンゲゼルシヤフト | ピリミジン誘導体およびその製造法 |
| BR9713363B1 (pt) * | 1996-11-18 | 2011-02-08 | processo para preparação de epotilona d. | |
| FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| CZ298027B6 (cs) * | 1997-02-25 | 2007-05-30 | Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) | Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu |
| GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6498257B1 (en) * | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| DE19826988A1 (de) * | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| AU765957B2 (en) * | 1998-10-01 | 2003-10-02 | Powderject Research Limited | Spray coated microparticles for use in needleless syringes |
| ES2291194T3 (es) * | 1999-02-18 | 2008-03-01 | Bayer Schering Pharma Aktiengesellschaft | Derivados de 16-halogeno-epotilones, procedimiento acerca de su preparacion y su utilizacion farmaceutica. |
| CZ301498B6 (cs) * | 1999-02-22 | 2010-03-24 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | C-21 modifikované epothilony |
| US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| IL149030A0 (en) * | 2000-08-09 | 2002-11-10 | Panacea Biotec Ltd | Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| MXPA03002521A (es) * | 2000-09-22 | 2004-02-12 | Biotechnolog Forschung Gmbh | Triazol-epotilona. |
| EP1191127B1 (de) | 2000-09-26 | 2004-10-13 | Enthone-OMI (Deutschland) GmbH | Verfahren zur selektiven Metallisierung dielektrischer Materialien |
| EE200300323A (et) * | 2001-01-25 | 2003-10-15 | Bristol-Myers Squibb Company | Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine |
| NZ526871A (en) * | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| CN100341505C (zh) * | 2001-01-25 | 2007-10-10 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗癌症的埃博霉素类似物的给药方法 |
| KR20040025895A (ko) * | 2001-02-20 | 2004-03-26 | 브리스톨-마이어스스퀴브컴파니 | 에포틸론 유도체를 사용하는 치료불응성 종양의 치료 |
| HUP0400041A2 (hu) * | 2001-02-20 | 2004-04-28 | Bristol-Myers Squibb Co. | Epotilonszármazékok alkalmazása makacs tumorok kezelésére szolgáló gyógyszerkészítmények előállítására |
| WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| JP2004532888A (ja) * | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| JP4645789B2 (ja) * | 2001-06-18 | 2011-03-09 | Ｊｓｒ株式会社 | ネガ型感放射線性樹脂組成物 |
| AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| DE60330651D1 (en) * | 2002-03-12 | 2010-02-04 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| EP1539111A1 (en) * | 2002-08-05 | 2005-06-15 | DSM IP Assets B.V. | Oral dosage forms of water insoluble drugs and methods of making the same |
| AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20060134214A1 (en) * | 2004-11-18 | 2006-06-22 | Ismat Ullah | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
-
2005
- 2005-11-17 KR KR1020077011236A patent/KR20070084325A/ko not_active Application Discontinuation
- 2005-11-17 DK DK05824194T patent/DK1817013T3/da active
- 2005-11-17 DE DE602005007376T patent/DE602005007376D1/de not_active Expired - Fee Related
- 2005-11-17 SI SI200530318T patent/SI1817013T1/sl unknown
- 2005-11-17 EP EP05824194A patent/EP1817013B1/en active Active
- 2005-11-17 MX MX2007005763A patent/MX2007005763A/es active IP Right Grant
- 2005-11-17 RU RU2007122627/15A patent/RU2349319C1/ru not_active IP Right Cessation
- 2005-11-17 CA CA002588400A patent/CA2588400A1/en not_active Abandoned
- 2005-11-17 US US11/281,855 patent/US20060153917A1/en not_active Abandoned
- 2005-11-17 JP JP2007543252A patent/JP2008520696A/ja not_active Withdrawn
- 2005-11-17 BR BRPI0518286-7A patent/BRPI0518286A2/pt not_active IP Right Cessation
- 2005-11-17 WO PCT/US2005/041736 patent/WO2006055740A1/en active Application Filing
- 2005-11-17 CN CNA2005800393851A patent/CN101083978A/zh active Pending
- 2005-11-17 PE PE2005001348A patent/PE20061058A1/es not_active Application Discontinuation
- 2005-11-17 AT AT05824194T patent/ATE397442T1/de not_active IP Right Cessation
- 2005-11-17 AU AU2005306464A patent/AU2005306464A1/en not_active Abandoned
- 2005-11-17 EP EP08008815A patent/EP1958625A1/en not_active Withdrawn
- 2005-11-17 ES ES05824194T patent/ES2306278T3/es active Active
- 2005-11-17 PT PT05824194T patent/PT1817013E/pt unknown
- 2005-11-17 TW TW094140483A patent/TW200631609A/zh unknown
- 2005-11-17 PL PL05824194T patent/PL1817013T3/pl unknown
- 2005-11-17 AR ARP050104839A patent/AR052142A1/es unknown
-
2007
- 2007-05-09 NO NO20072388A patent/NO20072388L/no not_active Application Discontinuation
- 2007-05-10 IL IL183116A patent/IL183116A0/en unknown
- 2007-05-16 ZA ZA200703955A patent/ZA200703955B/xx unknown
-
2008
- 2008-01-10 HK HK08100342A patent/HK1106713A1/xx not_active IP Right Cessation
- 2008-07-31 HR HR20080349T patent/HRP20080349T3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005007376D1 (de) | 2008-07-17 |
| JP2008520696A (ja) | 2008-06-19 |
| HK1106713A1 (en) | 2008-03-20 |
| US20060153917A1 (en) | 2006-07-13 |
| EP1817013A1 (en) | 2007-08-15 |
| IL183116A0 (en) | 2007-09-20 |
| HRP20080349T3 (en) | 2009-01-31 |
| DK1817013T3 (da) | 2008-10-13 |
| WO2006055740A1 (en) | 2006-05-26 |
| TW200631609A (en) | 2006-09-16 |
| KR20070084325A (ko) | 2007-08-24 |
| BRPI0518286A2 (pt) | 2008-11-11 |
| EP1817013B1 (en) | 2008-06-04 |
| NO20072388L (no) | 2007-06-14 |
| EP1958625A1 (en) | 2008-08-20 |
| SI1817013T1 (sl) | 2008-12-31 |
| CA2588400A1 (en) | 2006-05-26 |
| ZA200703955B (en) | 2008-08-27 |
| MX2007005763A (es) | 2007-07-20 |
| PL1817013T3 (pl) | 2009-01-30 |
| CN101083978A (zh) | 2007-12-05 |
| PT1817013E (pt) | 2008-08-07 |
| RU2349319C1 (ru) | 2009-03-20 |
| AU2005306464A1 (en) | 2006-05-26 |
| ES2306278T3 (es) | 2008-11-01 |
| AR052142A1 (es) | 2007-03-07 |
| ATE397442T1 (de) | 2008-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061058A1 (es) | Composicion farmaceutica que comprende ixabepilona y proceso de preparacion | |
| JP2015078230A5 (es) | ||
| JP2012255026A5 (es) | ||
| PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| ES2530681T3 (es) | Composiciones farmacéuticas flotantes de liberación controlada | |
| JP2018529656A5 (es) | ||
| PE20140163A1 (es) | Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato | |
| PH12015502134B1 (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
| PE20110544A1 (es) | Formulacion farmaceutica de liberacion controlada que comprende isomero r de lansoprazol | |
| PE20141115A1 (es) | Comprimido de desintegracion oral | |
| JP2017517556A5 (es) | ||
| JP2013518107A5 (es) | ||
| PE20110019A1 (es) | Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina | |
| PE20080765A1 (es) | Formas de dosificacion farmaceutica | |
| JP2012158592A5 (es) | ||
| JP2017519027A5 (es) | ||
| MX2014001167A (es) | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. | |
| CL2009000816A1 (es) | Metodos para modificar una estructura especifica asociada a una actividad biologica; ysu uso en el tratamiento de enfermedades y sintomas como son autoinmune, oculares, snc, cancer, entre otras. | |
| RU2014105577A (ru) | Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин | |
| JP2011519967A5 (es) | ||
| JP2016501013A5 (es) | ||
| JP2016539156A5 (es) | ||
| EA201992230A1 (ru) | Улучшенные фармацевтические композиции пимобендана | |
| JP2012504560A5 (es) | ||
| CO6220900A2 (es) | Forma dosificadora novedosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |